2-piperidone has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amini, RM; Apollonio, B; Awan, FT; Chiu, H; Fanous, M; Gandhi, AK; Hagner, PR; Ioannou, N; Janardhanan, P; Jones, J; Kay, NE; Lopez-Girona, A; Papazoglou, D; Patten, PEM; Ramsay, AG; Rosenquist, R; Shanafelt, TD; Stamatopoulos, K; Stokes, M; Sutton, LA; Tallman, MS; Vardi, A | 1 |
| Catherwood, MA; Kliszczak, AE; Montagnoli, A; Murillo, LS; Natoni, A; O'Dwyer, M; Samali, A; Santocanale, C | 1 |
2 other study(ies) available for 2-piperidone and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Topics: Animals; Antineoplastic Agents; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Mice; Piperidones; Quinazolinones; Signal Transduction; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; CD40 Ligand; Cell Cycle; Cell Cycle Proteins; Cells, Cultured; Cyclin-Dependent Kinase 9; DNA Replication; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; NIH 3T3 Cells; Phosphorylation; Piperidones; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA Polymerase II; Signal Transduction | 2011 |